Specializing in early discovery activity in the arena of recombinant biotherapeutic medicines, GigaGen, Inc. developed droplet microfluidics methods to perform massively parallel single cell genetic analysis. One of the firm's investors had been the Spanish firm Grifols (NASDAQ:GRFC) - specialist in plasma. That firm is now reported (March 2021)) to have acquired GigaGen in an $80M transaction. GigaGen offers single cell droplet technology that combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Relavent in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection applications, GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the worldâs first recombinant polyclonal hyperimmune gammaglobulin. Organized around a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation, the firm's proprietary antibody discovery technology has the capacity quickly to characterize every cell in complex immune systems, powering a selection of drug targets, identification of drug candidates and preclinical assessment of efficacy
